Intranasal Oxytocin for Obesity
Franziska Plessow(Harvard University), Elizabeth A. Lawson(Harvard University), Martin Torriani(Harvard University), Aluma Chovel Sella(Harvard University), Francesca Galbiati(Universitat de Vic - Universitat Central de Catalunya), Fatima Cody Stanford(Massachusetts General Hospital), Elisa Asanza(Harvard University), Laura M. Holsen(Brigham and Women's Hospital), Mark Vangel(Massachusetts General Hospital), Anna Aulinas(Harvard University), Marie‐Louis Wronski(Harvard University), Tara M. Holmes(Harvard University), Brian C. Healy(Evidence (Italy)), Miriam A. Bredella(Massachusetts General Hospital), Sarah E. Smith(Harvard University), Jennifer J. Thomas(Massachusetts General Hospital), Katherine Holman(Harvard University), Madhusmita Misra(Harvard University), Julia Gydus(Harvard University), Kristine Hauser(Harvard University), Michelle L. O’Donoghue(Brigham and Women's Hospital), Kamryn T. Eddy(Harvard University), Arvin Kheterpal(Harvard University), Maged Muhammed(Harvard University), Liya Kerem(Harvard University)
Cited by 20
Related Papers
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
|Science|2022|2k
Definition and diagnostic criteria of clinical obesity
|The Lancet Diabetes & Endocrinology|2025|1.3k
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
|Circulation|2019|930